Iconovo AB (OSTO:ICO) 5-Year RORE % : -13.97% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ICO Iconovo AB OSTO:ICO
34 GF Score
Price kr1.08
GF Value kr0.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Iconovo AB 5-Year RORE %?

Iconovo AB OSTO:ICO -0.92% 34 5-Year RORE % is -13.97 as of Mar. 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 702 Medical Devices & Instruments companies, Iconovo AB ranks worse than 61.25% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Iconovo AB's 5-Year RORE % for the quarter that ended in Mar. 2026 was -13.97%.

The industry rank for Iconovo AB's 5-Year RORE % or its related term are showing as below:

OSTO:ICO's 5-Year RORE % is ranked worse than
61.25% of 702 companies
in the Medical Devices & Instruments industry
Industry Median: -5.13 vs OSTO:ICO: -13.97

Iconovo AB  (OSTO:ICO) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Iconovo AB 5-Year RORE % Related Terms


Iconovo AB 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Iconovo AB's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iconovo AB 5-Year RORE % Chart

Iconovo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.91 35.33 16.21 3.19 -9.78

Iconovo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 -0.72 -5.05 -9.78 -13.97

OSTO:ICO vs ABT, SYK, MDT: 5-Year RORE % Comparison

For the Medical Devices subindustry, Iconovo AB's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iconovo AB 5-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Iconovo AB's 5-Year RORE % falls into.


OSTO:ICO
34GF Score
Iconovo AB OSTO:ICO
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iconovo AB 5-Year RORE % Calculation

Iconovo AB's 5-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.93--3.024 )/( -14.994-0 )
=2.094/-14.994
=-13.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -13.97 mean?
Iconovo AB (OSTO:ICO) has a 5-Year RORE % of -13.97 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Iconovo AB and its competitors. According to the industry distribution chart, Iconovo AB ranks #430 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 61.3%.
Is Iconovo AB's 5-Year RORE % too high?
Iconovo AB's current 5-Year RORE % is -13.97. Based on the distribution chart, Iconovo AB ranks #430 out of 702 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's 5-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #430 out of 702 companies for 5-Year RORE %. This places Iconovo AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Iconovo AB and its competitors. Iconovo AB's current 5-Year RORE % is -13.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr1.08 — trading 300% above its estimated fair value. The current 5-Year RORE % is -13.97. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current 5-Year RORE % is -13.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iconovo AB (OSTO:ICO) Overvalued in 2026?

Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued. The current stock price of kr1.08 is trading 300% above its estimated GF Value™ of kr0.27. GuruFocus considers Iconovo AB to be Significantly Overvalued.

Key valuation signals for OSTO:ICO:

  • 5-Year RORE %: -13.97
  • GF Value™: kr0.27 vs. price of kr1.08 (300% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Iconovo AB Business Description

Address Ideongatan 3 A-B, Delta 6, Lund, SWE, SE-223 62
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score

Get the complete analysis for OSTO:ICO

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.08
Price
kr0.27
GF Value